Intraductal papillary mucinous neoplasms of the pancreas: An updated experience

Taylor A. Sohn, Charles J. Yeo, John L. Cameron, Ralph H. Hruban, Noriyoshi Fukushima, Kurtis A. Campbell, Keith D. Lillemoe, Andrew L. Warshaw, David B. Adams, William H. Nealon, Edward M. Coveland

Research output: Contribution to journalArticle

697 Citations (Scopus)

Abstract

Objective: To update the authors' experience with intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. Background Data: IPMNs are intraductal mucin-producing cystic neoplasms of the pancreas with clear malignant potential. Since the authors' 2001 report, the number of IPMNs resected at our institution has more than doubled, providing an opportunity to define the clinical features of this distinct neoplasm. Methods: All patients undergoing pancreatic resection for an IPMN at the Johns Hopkins Hospital between January 1987 and March 2003 were evaluated. Noninvasive IPMNs were classified as "adenoma," "borderline," or "carcinoma-in situ" (CIS) depending on the degree of dysplasia within the specimen. Invasive cancers were classified as tubular, colloid, mixed, or anaplastic types. Pathology was retrospectively reviewed to identify main-duct or branch-duct origin of the tumors. Long-term overall survival for patients having IPMNs with invasive cancer was compared with those patients having IPMNs without an invasive component. Results: Between January 1987 and March 2003, inclusive, 136 pancreatic resections were performed for patients with IPMNs, with 78 resections performed since January 2001. The mean age of the patients was 66.8 ± 1.1 years, with 57% being male and 89% white. Pancreaticoduodenectomy was performed in 71% of patients, total pancreatectomy in 15%, distal pancreatectomy in 12%, and central pancreatic resection in 2%. IPMNs without evidence of invasive cancer were identified in 62% (n = 84) of patients (17% adenoma, 28% borderline, or 55% CIS). The remaining 38% (n = 52) of patients had IPMNs with associated invasive cancer (60% tubular, 27% colloid, 7% mixed, and 6% anaplastic). The mean age of patients with IPMN adenoma was 63.2 years, 66.7 years for those with borderline/CIS IPMNs, and 68.1 years for those with invasive cancer (P = 0.08, adenomas vs. invasive cancer). In those patients with invasive cancers, 15% had invasive cancer at the final surgical margin, 23% had IPMN without invasive cancer at the margin, and 54% had lymph node metastases. Residual IPMN was identified at the neck or uncinate margin in 24% of patients with noninvasive IPMNs. The overall 5-year survival for patients having IPMNs without invasive cancer was 77% (several deaths secondary to metachronous invasive cancer), compared with 43% in those patients with an invasive component (P < 0.0001). There were no differences in survival when comparing adenomas, borderline neoplasms, and CIS. Similarly, there were no statistically significant differences in survival when comparing branch-duct, main-duct, and combined variants; however, the branch-duct variants were more often noninvasive. For those patients with invasive IPMNs, 2-year survival was 40% when margins were positive for invasive cancer or for IPMN without invasive cancer, and 60% when margins were tumor-free (P = 0.15). Those patients with colloid carcinomas (n = 14) had improved survival compared with those with tubular carcinomas (n = 31), with 5-year survival rates of 83% and 24%, respectively. IPMN recurrences and deaths from cancer occurred in patients with both invasive and noninvasive IPMNs at initial resection. Conclusions: IPMNs continue to be recognized with increasing frequency. Five-year survival for those patients following resection of IPMNs with invasive cancer (43%) is improved compared with those patients with resected pancreatic ductal adenocarcinoma in the absence of IPMN (averages 15%-25%). Survival following resection of IPMNs without invasive cancer (regardless of degree of dyplasia) is good, but recurrent disease in the residual pancreas suggests that long-term surveillance is critical. Based on the age at resection data, there appears to be a 5-year lag time from IPMN adenoma (63.2 years) to invasive cancer (68.1 years).

Original languageEnglish (US)
Pages (from-to)788-799
Number of pages12
JournalAnnals of Surgery
Volume239
Issue number6
DOIs
StatePublished - Jun 2004
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Neoplasms
Adenoma
Survival
Carcinoma in Situ
Pancreatectomy

ASJC Scopus subject areas

  • Surgery

Cite this

Sohn, T. A., Yeo, C. J., Cameron, J. L., Hruban, R. H., Fukushima, N., Campbell, K. A., ... Coveland, E. M. (2004). Intraductal papillary mucinous neoplasms of the pancreas: An updated experience. Annals of Surgery, 239(6), 788-799. https://doi.org/10.1097/01.sla.0000128306.90650.aa

Intraductal papillary mucinous neoplasms of the pancreas : An updated experience. / Sohn, Taylor A.; Yeo, Charles J.; Cameron, John L.; Hruban, Ralph H.; Fukushima, Noriyoshi; Campbell, Kurtis A.; Lillemoe, Keith D.; Warshaw, Andrew L.; Adams, David B.; Nealon, William H.; Coveland, Edward M.

In: Annals of Surgery, Vol. 239, No. 6, 06.2004, p. 788-799.

Research output: Contribution to journalArticle

Sohn, TA, Yeo, CJ, Cameron, JL, Hruban, RH, Fukushima, N, Campbell, KA, Lillemoe, KD, Warshaw, AL, Adams, DB, Nealon, WH & Coveland, EM 2004, 'Intraductal papillary mucinous neoplasms of the pancreas: An updated experience', Annals of Surgery, vol. 239, no. 6, pp. 788-799. https://doi.org/10.1097/01.sla.0000128306.90650.aa
Sohn TA, Yeo CJ, Cameron JL, Hruban RH, Fukushima N, Campbell KA et al. Intraductal papillary mucinous neoplasms of the pancreas: An updated experience. Annals of Surgery. 2004 Jun;239(6):788-799. https://doi.org/10.1097/01.sla.0000128306.90650.aa
Sohn, Taylor A. ; Yeo, Charles J. ; Cameron, John L. ; Hruban, Ralph H. ; Fukushima, Noriyoshi ; Campbell, Kurtis A. ; Lillemoe, Keith D. ; Warshaw, Andrew L. ; Adams, David B. ; Nealon, William H. ; Coveland, Edward M. / Intraductal papillary mucinous neoplasms of the pancreas : An updated experience. In: Annals of Surgery. 2004 ; Vol. 239, No. 6. pp. 788-799.
@article{9b6ba164100e45ff9d619889ca771fca,
title = "Intraductal papillary mucinous neoplasms of the pancreas: An updated experience",
abstract = "Objective: To update the authors' experience with intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. Background Data: IPMNs are intraductal mucin-producing cystic neoplasms of the pancreas with clear malignant potential. Since the authors' 2001 report, the number of IPMNs resected at our institution has more than doubled, providing an opportunity to define the clinical features of this distinct neoplasm. Methods: All patients undergoing pancreatic resection for an IPMN at the Johns Hopkins Hospital between January 1987 and March 2003 were evaluated. Noninvasive IPMNs were classified as {"}adenoma,{"} {"}borderline,{"} or {"}carcinoma-in situ{"} (CIS) depending on the degree of dysplasia within the specimen. Invasive cancers were classified as tubular, colloid, mixed, or anaplastic types. Pathology was retrospectively reviewed to identify main-duct or branch-duct origin of the tumors. Long-term overall survival for patients having IPMNs with invasive cancer was compared with those patients having IPMNs without an invasive component. Results: Between January 1987 and March 2003, inclusive, 136 pancreatic resections were performed for patients with IPMNs, with 78 resections performed since January 2001. The mean age of the patients was 66.8 ± 1.1 years, with 57{\%} being male and 89{\%} white. Pancreaticoduodenectomy was performed in 71{\%} of patients, total pancreatectomy in 15{\%}, distal pancreatectomy in 12{\%}, and central pancreatic resection in 2{\%}. IPMNs without evidence of invasive cancer were identified in 62{\%} (n = 84) of patients (17{\%} adenoma, 28{\%} borderline, or 55{\%} CIS). The remaining 38{\%} (n = 52) of patients had IPMNs with associated invasive cancer (60{\%} tubular, 27{\%} colloid, 7{\%} mixed, and 6{\%} anaplastic). The mean age of patients with IPMN adenoma was 63.2 years, 66.7 years for those with borderline/CIS IPMNs, and 68.1 years for those with invasive cancer (P = 0.08, adenomas vs. invasive cancer). In those patients with invasive cancers, 15{\%} had invasive cancer at the final surgical margin, 23{\%} had IPMN without invasive cancer at the margin, and 54{\%} had lymph node metastases. Residual IPMN was identified at the neck or uncinate margin in 24{\%} of patients with noninvasive IPMNs. The overall 5-year survival for patients having IPMNs without invasive cancer was 77{\%} (several deaths secondary to metachronous invasive cancer), compared with 43{\%} in those patients with an invasive component (P < 0.0001). There were no differences in survival when comparing adenomas, borderline neoplasms, and CIS. Similarly, there were no statistically significant differences in survival when comparing branch-duct, main-duct, and combined variants; however, the branch-duct variants were more often noninvasive. For those patients with invasive IPMNs, 2-year survival was 40{\%} when margins were positive for invasive cancer or for IPMN without invasive cancer, and 60{\%} when margins were tumor-free (P = 0.15). Those patients with colloid carcinomas (n = 14) had improved survival compared with those with tubular carcinomas (n = 31), with 5-year survival rates of 83{\%} and 24{\%}, respectively. IPMN recurrences and deaths from cancer occurred in patients with both invasive and noninvasive IPMNs at initial resection. Conclusions: IPMNs continue to be recognized with increasing frequency. Five-year survival for those patients following resection of IPMNs with invasive cancer (43{\%}) is improved compared with those patients with resected pancreatic ductal adenocarcinoma in the absence of IPMN (averages 15{\%}-25{\%}). Survival following resection of IPMNs without invasive cancer (regardless of degree of dyplasia) is good, but recurrent disease in the residual pancreas suggests that long-term surveillance is critical. Based on the age at resection data, there appears to be a 5-year lag time from IPMN adenoma (63.2 years) to invasive cancer (68.1 years).",
author = "Sohn, {Taylor A.} and Yeo, {Charles J.} and Cameron, {John L.} and Hruban, {Ralph H.} and Noriyoshi Fukushima and Campbell, {Kurtis A.} and Lillemoe, {Keith D.} and Warshaw, {Andrew L.} and Adams, {David B.} and Nealon, {William H.} and Coveland, {Edward M.}",
year = "2004",
month = "6",
doi = "10.1097/01.sla.0000128306.90650.aa",
language = "English (US)",
volume = "239",
pages = "788--799",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Intraductal papillary mucinous neoplasms of the pancreas

T2 - An updated experience

AU - Sohn, Taylor A.

AU - Yeo, Charles J.

AU - Cameron, John L.

AU - Hruban, Ralph H.

AU - Fukushima, Noriyoshi

AU - Campbell, Kurtis A.

AU - Lillemoe, Keith D.

AU - Warshaw, Andrew L.

AU - Adams, David B.

AU - Nealon, William H.

AU - Coveland, Edward M.

PY - 2004/6

Y1 - 2004/6

N2 - Objective: To update the authors' experience with intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. Background Data: IPMNs are intraductal mucin-producing cystic neoplasms of the pancreas with clear malignant potential. Since the authors' 2001 report, the number of IPMNs resected at our institution has more than doubled, providing an opportunity to define the clinical features of this distinct neoplasm. Methods: All patients undergoing pancreatic resection for an IPMN at the Johns Hopkins Hospital between January 1987 and March 2003 were evaluated. Noninvasive IPMNs were classified as "adenoma," "borderline," or "carcinoma-in situ" (CIS) depending on the degree of dysplasia within the specimen. Invasive cancers were classified as tubular, colloid, mixed, or anaplastic types. Pathology was retrospectively reviewed to identify main-duct or branch-duct origin of the tumors. Long-term overall survival for patients having IPMNs with invasive cancer was compared with those patients having IPMNs without an invasive component. Results: Between January 1987 and March 2003, inclusive, 136 pancreatic resections were performed for patients with IPMNs, with 78 resections performed since January 2001. The mean age of the patients was 66.8 ± 1.1 years, with 57% being male and 89% white. Pancreaticoduodenectomy was performed in 71% of patients, total pancreatectomy in 15%, distal pancreatectomy in 12%, and central pancreatic resection in 2%. IPMNs without evidence of invasive cancer were identified in 62% (n = 84) of patients (17% adenoma, 28% borderline, or 55% CIS). The remaining 38% (n = 52) of patients had IPMNs with associated invasive cancer (60% tubular, 27% colloid, 7% mixed, and 6% anaplastic). The mean age of patients with IPMN adenoma was 63.2 years, 66.7 years for those with borderline/CIS IPMNs, and 68.1 years for those with invasive cancer (P = 0.08, adenomas vs. invasive cancer). In those patients with invasive cancers, 15% had invasive cancer at the final surgical margin, 23% had IPMN without invasive cancer at the margin, and 54% had lymph node metastases. Residual IPMN was identified at the neck or uncinate margin in 24% of patients with noninvasive IPMNs. The overall 5-year survival for patients having IPMNs without invasive cancer was 77% (several deaths secondary to metachronous invasive cancer), compared with 43% in those patients with an invasive component (P < 0.0001). There were no differences in survival when comparing adenomas, borderline neoplasms, and CIS. Similarly, there were no statistically significant differences in survival when comparing branch-duct, main-duct, and combined variants; however, the branch-duct variants were more often noninvasive. For those patients with invasive IPMNs, 2-year survival was 40% when margins were positive for invasive cancer or for IPMN without invasive cancer, and 60% when margins were tumor-free (P = 0.15). Those patients with colloid carcinomas (n = 14) had improved survival compared with those with tubular carcinomas (n = 31), with 5-year survival rates of 83% and 24%, respectively. IPMN recurrences and deaths from cancer occurred in patients with both invasive and noninvasive IPMNs at initial resection. Conclusions: IPMNs continue to be recognized with increasing frequency. Five-year survival for those patients following resection of IPMNs with invasive cancer (43%) is improved compared with those patients with resected pancreatic ductal adenocarcinoma in the absence of IPMN (averages 15%-25%). Survival following resection of IPMNs without invasive cancer (regardless of degree of dyplasia) is good, but recurrent disease in the residual pancreas suggests that long-term surveillance is critical. Based on the age at resection data, there appears to be a 5-year lag time from IPMN adenoma (63.2 years) to invasive cancer (68.1 years).

AB - Objective: To update the authors' experience with intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. Background Data: IPMNs are intraductal mucin-producing cystic neoplasms of the pancreas with clear malignant potential. Since the authors' 2001 report, the number of IPMNs resected at our institution has more than doubled, providing an opportunity to define the clinical features of this distinct neoplasm. Methods: All patients undergoing pancreatic resection for an IPMN at the Johns Hopkins Hospital between January 1987 and March 2003 were evaluated. Noninvasive IPMNs were classified as "adenoma," "borderline," or "carcinoma-in situ" (CIS) depending on the degree of dysplasia within the specimen. Invasive cancers were classified as tubular, colloid, mixed, or anaplastic types. Pathology was retrospectively reviewed to identify main-duct or branch-duct origin of the tumors. Long-term overall survival for patients having IPMNs with invasive cancer was compared with those patients having IPMNs without an invasive component. Results: Between January 1987 and March 2003, inclusive, 136 pancreatic resections were performed for patients with IPMNs, with 78 resections performed since January 2001. The mean age of the patients was 66.8 ± 1.1 years, with 57% being male and 89% white. Pancreaticoduodenectomy was performed in 71% of patients, total pancreatectomy in 15%, distal pancreatectomy in 12%, and central pancreatic resection in 2%. IPMNs without evidence of invasive cancer were identified in 62% (n = 84) of patients (17% adenoma, 28% borderline, or 55% CIS). The remaining 38% (n = 52) of patients had IPMNs with associated invasive cancer (60% tubular, 27% colloid, 7% mixed, and 6% anaplastic). The mean age of patients with IPMN adenoma was 63.2 years, 66.7 years for those with borderline/CIS IPMNs, and 68.1 years for those with invasive cancer (P = 0.08, adenomas vs. invasive cancer). In those patients with invasive cancers, 15% had invasive cancer at the final surgical margin, 23% had IPMN without invasive cancer at the margin, and 54% had lymph node metastases. Residual IPMN was identified at the neck or uncinate margin in 24% of patients with noninvasive IPMNs. The overall 5-year survival for patients having IPMNs without invasive cancer was 77% (several deaths secondary to metachronous invasive cancer), compared with 43% in those patients with an invasive component (P < 0.0001). There were no differences in survival when comparing adenomas, borderline neoplasms, and CIS. Similarly, there were no statistically significant differences in survival when comparing branch-duct, main-duct, and combined variants; however, the branch-duct variants were more often noninvasive. For those patients with invasive IPMNs, 2-year survival was 40% when margins were positive for invasive cancer or for IPMN without invasive cancer, and 60% when margins were tumor-free (P = 0.15). Those patients with colloid carcinomas (n = 14) had improved survival compared with those with tubular carcinomas (n = 31), with 5-year survival rates of 83% and 24%, respectively. IPMN recurrences and deaths from cancer occurred in patients with both invasive and noninvasive IPMNs at initial resection. Conclusions: IPMNs continue to be recognized with increasing frequency. Five-year survival for those patients following resection of IPMNs with invasive cancer (43%) is improved compared with those patients with resected pancreatic ductal adenocarcinoma in the absence of IPMN (averages 15%-25%). Survival following resection of IPMNs without invasive cancer (regardless of degree of dyplasia) is good, but recurrent disease in the residual pancreas suggests that long-term surveillance is critical. Based on the age at resection data, there appears to be a 5-year lag time from IPMN adenoma (63.2 years) to invasive cancer (68.1 years).

UR - http://www.scopus.com/inward/record.url?scp=2442717796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442717796&partnerID=8YFLogxK

U2 - 10.1097/01.sla.0000128306.90650.aa

DO - 10.1097/01.sla.0000128306.90650.aa

M3 - Article

C2 - 15166958

AN - SCOPUS:2442717796

VL - 239

SP - 788

EP - 799

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 6

ER -